Monitoring of Anticoagulant Assays
There is no established laboratory method for monitoring dabigatran’s activity. While its short half-life and reliable pharmacokinetics render this unnecessary for routine clinical use, it may be advantageous in the setting of a potential overdose or clinically significant bleeding. PT/INR, activated partial thromboplastin time (aPTT), thrombin clotting time (TT), ecarin clotting time (ECT), activated clotting time (ACT), and fibrinogen tests have all been evaluated as potential measures of the anticoagulant effect of dabigatran.
While monitoring of the PT/INR is standard for warfarin therapy, it is relatively insensitive to dabigatran’s effect at therapeutic levels [
3‐
5]. In contrast, the aPTT increases in a curvilinear fashion with increasing dabigatran concentration, but the concentration-response curve plateaus at dabigatran concentrations above 200 ng/mL [
3‐
7], which is close to the peak therapeutic level achieved by most patients [
8]. Thus, the aPTT is a sensitive test for detecting dabigatran activity, but its value may not accurately reflect dabigatran concentrations above therapeutic levels. Similarly, in vitro studies show a linear relationship between the ACT and dabigatran concentrations up to 250 ng/mL, with a flattening of the concentration-response curve above 500 ng/mL [
3]. However, the ACT has not been systematically tested in patients and, therefore, its clinical utility remains uncertain.
The TT directly assesses thrombin activity and exhibits a linear relationship with increasing dabigatran concentration up to 600 ng/mL, at which point the value generally exceeds the maximum measurement time of most coagulometers [
3,
6]. Thus, the standard TT may be most useful in determining the presence or absence of circulating dabigatran, but may be too sensitive for overdose evaluations [
3‐
5,
7,
9]. The HemoClot
® thrombin inhibitor assay (Hyphen BioMed, Neuville-sur-Oise, France) is not yet commercially available in the US, but holds promise as a useful assay for determining drug concentration [
3,
4,
7,
9]. The diluted TT assay exhibits a linear relationship with dabigatran concentrations, even at high levels. Thus, dabigatran standards can be supplied to run a calibration curve and thereby determine plasma dabigatran concentration. The ECT is another promising assay of thrombin generation that exhibits a linear relationship with plasma concentrations of dabigatran [
3,
5]. However, ECT is currently only available in the research setting [
9] and was not available at the authors’ institution.
Dabigatran was developed with the expectation that routine laboratory monitoring of its anticoagulant effect would not be needed. However, the present patient’s case demonstrates the utility of adopting standardized testing to determine plasma dabigatran concentration. Although initial fibrinogen concentration was in the normal range at 279 mg/dL, the presence of hepatic failure in the present patient made it difficult to determine the degree of coagulopathy attributable to dabigatran versus the contribution from impaired hepatic synthetic function.
Use of Dabigatran in Elderly Patients
Numerous case reports of serious bleeding on dabigatran have been reported in the elderly [
7,
10‐
16]. As in the present patient, these events are frequently precipitated by development of acute renal failure. In patients with normal renal function, dabigatran’s half-life is 12–17 h [
12]. In patients with a creatinine clearance (CrCl) between 30–50 mL/min, the half-life increases to 13–23 h [
12]. As the CrCl falls below 30 mL/min, dabigatran’s half-life increases to 22–35 h [
12]. For patients with a baseline CrCl of 15–30 mL/min or CrCl of 30–50 mL/min receiving concomitant treatment with strong inhibitors of P-glycoprotein (P-gp), the FDA has approved a dabigatran dose of 75 mg twice-daily [
17]. Of note, the RE-LY trial excluded patients with a CrCl less than 30 mL/min and, thus, both the efficacy and relative bleeding risk as compared with warfarin have not been established in this population [
1].
Although several case reports implicate development of acute renal failure as the cause for excessive anticoagulation with dabigatran use in the elderly, there are no established guidelines for monitoring renal function while on dabigatran [
10‐
12]. The Italian Federation of Thrombosis Centers recommends annual assessment of renal function in patients with mild renal failure and bi-annual assessments in patients with moderate renal failure [
18]. In November of 2011, the prescribing information for dabigatran was revised to recommend calculation of CrCl prior to drug initiation, in any clinical situation potentially associated with a decline in renal function, and annual monitoring in patients greater than 75 years of age or with a CrCl less than 50 mL/min [
12,
19]. Close monitoring of CrCl may enable detection of asymptomatic changes in renal function that warrant dose adjustments or cessation of the drug.
In an analysis from the RE-LY trial, patients aged less than 75 years experienced less bleeding with both dabigatran 110 and 150 mg as compared to warfarin (1.89% versus 3.04%,
P < 0.001 for 110 mg; 2.12% versus 3.04%,
P < 0.001 for 150 mg) [
20]. Among patients aged 75 years and older, however, the risk of bleeding with dabigatran 110 mg was similar to that of warfarin (4.43% versus 4.37%,
P = 0.89), but a trend toward increased risk of bleeding with age emerged with dabigatran 150 mg as compared with warfarin (5.10% versus 4.37%,
P = 0.07;
P for interaction <0.001) [
20]. When the type of bleeding was further analyzed, an increased risk of extracranial bleeding with age emerged, but the risk of intracranial bleeding remained lower for dabigatran as compared with warfarin regardless of age [
20]. Interestingly, patients with CrCl <50 mL/min experienced a more than twofold increased risk of major bleeding with both dabigatran and warfarin as compared to patients with CrCl ≥80 mL/min even though warfarin, unlike dabigatran, is not renally excreted [
20]. Given a lack of association between treatment and CrCl with major bleeding, factors other than a tendency toward impaired renal function may contribute to the increased risk of extracranial bleeding that elderly patients experience with dabigatran therapy [
20].
Because dabigatran is not metabolized by the cytochrome (CYP) P450 system, drugs affecting CYP enzymes should not affect dabigatran [
5,
21]. Dabigatran is, however, a substrate of the efflux transporter P-gp [
17]. Inducers of P-gp (e.g., rifampin) decrease peak dabigatran concentrations, while P-gp inhibitors (e.g., ketoconazole and dronedarone) increase peak concentrations. This latter interaction is of particular importance in patients with renal impairment in whom dose adjustments of dabigatran or avoidance of the P-gp inhibitor should be considered depending on the specific co-administered drug and degree of renal impairment [
5,
17,
21]. Of note, no dose adjustment of dabigatran is recommended in combination with moderate P-gp inhibitors (e.g., verapamil, amiodarone, quinidine, and clarithromycin) [
17].
Methods for Reversal of Dabigatran’s Anticoagulant Effect
Reports of major bleeding in patients receiving dabigatran have garnered attention in large part due to the fact that, unlike warfarin, there is currently no antidote for its anticoagulant effect. Given its relatively short half-life (12–17 h) compared to vitamin K antagonists, drug cessation and supportive care is often sufficient in patients with normal renal function who will excrete the drug within hours [
3,
10,
12,
14,
22]. By 12 h, dabigatran plasma concentrations fall below 100 ng/mL and aPTT falls to 1.5 times baseline values in patients with normal renal function taking 150 mg of dabigatran twice-daily [
3]. Even with impaired CrCl, promoting diuresis when possible is encouraged as a means of eliminating the drug [
7]. As shown in Fig.
3, the present patient’s coagulation parameters improved in conjunction with improving renal function. When overdose is suspected, dabigatran can be absorbed by activated charcoal given within 1–2 h of ingestion, although this has only been tested in vitro [
3,
6,
23]. However, case reports of dabigatran overdose cite new renal failure rather than either intentional or accidental ingestion as the usual culprit, limiting the utility of this potential method [
12,
13,
15,
16].
Many therapies used to reverse other anticoagulants are ineffective with dabigatran. Vitamin K and protamine sulfate, well-known antidotes of warfarin and heparin, respectively, are not beneficial for over-anticoagulation with dabigatran [
3,
22]. Use of cryoprecipitate has been cited in two case reports without clinical benefit [
16,
24]. While the 2011 focused update on the management of patients with atrial fibrillation (update on dabigatran) from the American College of Cardiology, American Heart Association, and Heart Rhythm Society suggest the use of FFP, many cases report utilization of FFP without a significant change in the aPTT or INR [
3,
6,
22,
23,
25].
Recombinant activated factor VII (rFVIIa) was developed for treatment of bleeding in hemophiliac patients with inhibitors to factors VIII and IX. Exogenous factor VIIa can directly activate thrombin on the surface of platelets in the absence of tissue factor and has, therefore, gained interest as a potential means of reversing dabigatran’s effect [
3,
6,
23]. However, rFVIIa did not reverse the antithrombotic effects of melagatran (the active form of the oral direct thrombin inhibitor, ximelagatran, which is not available for clinical use) in a single-blind, randomized study of 47 healthy male volunteers [
26].
In an ex vivo study of eight patients with atrial fibrillation taking dabigatran 150 mg twice-daily, Davis et al. [
27] investigated the Rapid Thromboelastographic-derived activated clotting time (RapidTEG-ACT) as a method of measuring both the anticoagulant activity of dabigatran and the potential for reversibility with human inactivated thrombin (HTI), rFVIIa, and a four-factor PCC. In concert with aPTT, PT, TT, and ACT, measurement of reaction time from test initiation to initial fibrin formation using thromboelastography (called the TEG
R-value) is a potentially useful laboratory value for assessing dabigatran’s anticoagulant activity. The addition of HTI (currently only available topically and, therefore, unsuited for in vivo testing for this indication) and rFVIIa to patients’ peripheral blood significantly reduced the TEG
R-value while the PCC analog did not. This study suggests a potential utility for rFVIIa that requires further investigation in vivo and clinically.
In a case report of a 79-year-old participant in the RE-LY trial who unintentionally underwent cardiac surgery with therapeutic levels of circulating dabigatran, the authors reported initially trying three doses of 2.4 mg/dose of rFVIIa without success in controlling the patient’s post-operative bleeding [
24]. The authors subsequently administered two doses of 7.2 mg/dose and, although they did not report coagulation parameters, they cited a reduction in the patient’s bleeding as a favorable sign that high-dose rFVIIa may reduce dabigatran-associated bleeding. However, the patient also underwent hemodialysis (HD), which may have contributed to the reduction in bleeding. Furthermore, given the potential of rFVIIa to precipitate myocardial infarction and stroke, care should be taken in using rFVIIa for bleeding events in non-hemophiliacs. The FDA has issued a black box warning due to an increased potential for thrombotic events when rVIIa is used outside of the product’s approved indications [
28].
Several cases reports, including the present, have commented on the utilization of PCC, of which there are two types available [
12,
23]. In the US, only three-factor concentrates are available. They contain II, IX, and X but very low levels of VII. Profilnine is a three-factor PCC used in the authors’ institution. Cofact
® (Sanquin, Amsterdam, The Netherlands) is a four-factor PCC that contains higher levels of factor VII and is available in Canada and several European countries. In a randomized, double-blind trial of 12 healthy male volunteers, 50 IU/kg of Cofact did not reverse the anticoagulant effects of dabigatran as measured using aPTT, ECT, or TT [
29]. In the present case, the patient’s coagulopathy did rapidly correct, but the independent contribution of Profilnine could not be determined as it was administered concomitantly with vitamin K and FFP (Fig.
3).
An activated PCC (aPCC) available in the US is Factor Eight Inhibitory Bypassing Activity (FEIBA
®; FEIBA NF
®, Baxter, West Lake Village, CA, USA). This product is an aPCC concentrate containing factors II, activated VII, IX, and X that was developed for hemophiliac patients with inhibitors to factors VIII or IX. FEIBA has the theoretical benefit of combining the effects of rFVIIa and PCC [
23,
30]. In vitro, FEIBA decreased the aPTT of plasma containing factor VIII inhibitor [
30]. Marlu et al. [
31] assessed whether PCC, rFVIIa, or FEIBA could reverse the anticoagulant effect of dabigatran 150 mg in vitro using venous blood from ten, healthy, white male patients. Four-factor PCC and FEIBA increased the endogenous thrombin potential of dabigatran-anticoagulated plasma, with low doses successfully reducing levels back to baseline and regular or half doses actually increasing thrombin generation. The highest dose of rFVIIa (3 U/mL) and the three highest doses of FEIBA (0.5–2 U/mL) corrected lag time in thrombin generation nearly to baseline. This study suggests that these products remain promising with respect to reversal of dabigatran-induced thrombin inhibition.
Finally, a number of novel reversal agents are currently in various stages of development. Van Ryn et al. [
32] reported that a humanized monoclonal antibody fragment (Fab) against dabigatran can completely inhibit the anticoagulant activity of the drug in both human plasma and whole blood. A synthetic small molecule, PER977, is being developed as a potential antidote to all novel oral anticoagulant drugs, with activity against factor Xa and IIa inhibitors [
33]. In addition, a truncated, inactive form of factor Xa known as PRT064445 is currently being tested in phase 2 clinical trials. Early in vitro and in vivo studies have shown this compound to be an effective reversal agent for both the newer direct factor Xa inhibitors and indirect factor Xa inhibitors, such as low molecular weight heparin and fondaparinux [
33‐
36].